Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy
The SREBP1-PCSK9 axis-mediated lipid metabolism is crucial for triggering immune evasion and resistance to anti-PD-1. Targeting the SREBP1-PCSK9 axis could potentially reverse PDAC's resistance to anti-PD-1 therapy.
Authors
- Hanjia Zhang (ORCID: https://orcid.org/0000-0003-4416-7833)
- Hanshen Yang (ORCID: https://orcid.org/0000-0001-5220-1996)
- Lihong He (ORCID: https://orcid.org/0000-0002-2694-2974)
- Xueli Bai (ORCID: https://orcid.org/0000-0002-2934-0880)
- Yan Chen (ORCID: https://orcid.org/0000-0002-5301-185X)
- Mengyi Lao (ORCID: https://orcid.org/0000-0003-3650-5345)
- Daqian Xu (ORCID: https://orcid.org/0000-0003-0478-2997)
- Kang Sun (ORCID: https://orcid.org/0000-0003-0240-0908)
- Sicheng Wang (ORCID: https://orcid.org/0000-0002-5224-5697)
- Tingbo Liang
- Zejun Li (ORCID: https://orcid.org/0000-0002-8751-9387)
- Xiaozhen Zhang (ORCID: https://orcid.org/0000-0003-3567-8789)
- Jiatao Shi
Institutions
- Zhejiang Cancer Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Indiana University School of Medicine
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer Communications
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1002/cac2.70038
- Citations
- 9
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 9.41
Funders
- National Natural Science Foundation of China